RCR COIN/BAUS – Guidelines on the management of prostate cancer – 1999

Authors : Representatives of the British Association of Urological Surgeons, the Clinical Oncology Information Network, the Medical Research Council Prostate Advisory Group, the British prostate Group.

References

Level of evidence (1a – IV) as used by US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research.

Grade

Grade of recommendations (A – C) as used by US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research.

Coverage

Covers diagnosis + staging as well as the management of early, locally
advanced, metastatic and hormone refractory disease. In addition there is a section on patient support and information.

With respect to management examples of the recommendations include:

• Locally Advanced Disease – optimal management is problematic.
  
  Options include watchful waiting, hormonal therapy alone, radiotherapy with or without initial (neoadjuvant) or adjuvant androgen deprivation.
  
  For locally advanced (T3-4) disease, neo-adjuvant or adjuvant hormone therapy should be considered for patients who are treated with radical radiotherapy.
  
  
• Metastatic Disease – some form of hormone manipulation should be considered with all patients with metastatic disease and offered to all patients with symptoms of metastatic disease.
  
  First line treatment should be either orchidectomy or LHRH analogue by monthly or three monthly depot injection.
  
  Patients commencing hormone therapy should be offered a choice between orchidectomy or LHRH analogues as the first line therapy.

Source

Please follow this link for a full version of the RCR Guidelines